Your trusted source for investing success

Tag: drugs

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 
What Is In-Licensing?

What Is In-Licensing?

Licensing deals might be pharma’s preferred mode of business development these days—perhaps even more so than outright acquisitions.

Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen

Akcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced that the Division of Metabolism and Endocrinology Products of the U.S. Food and Drug Administration (FDA) will hold an advisory committee meeting to review

Isodiol International Inc. Signs Definitive Agreement to Acquire 100% Of Canadian National Pharma Group Inc.

Isodiol International Inc. Signs Definitive Agreement to Acquire 100% Of Canadian National Pharma Group Inc.

Isodiol International Inc. (CSE:ISOL, OTC:LAGBF, FSE:LBGA.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a Definitive Agreement to acquire 100% of Canadian National Pharma Group Inc. (CN Pharma), a pharmaceutical manufacturing company.

Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M

Actinium Pharmaceuticals (NYSE:ATNM) announced that an Investigational New Drug application has been submitted with the U.S. Food and Drug Administration (FDA) for Actimab-A in combination with CLAG-M for relapsed or refractory Acute Myeloid Leukemia patients.

As quoted in the press release:
Dr. Mark Berger, Actinium’s Chief Medical Officer said, “CLAG-M has become a

Isodiol International Inc. Announces Partnership With Europe’s Leading MMA Promotion, Cage Warriors; ISO-Sport Product Line to Commence Sales in the European Market

Isodiol International Inc. Announces Partnership With Europe’s Leading MMA Promotion, Cage Warriors; ISO-Sport Product Line to Commence Sales in the European Market

Isodiol International LLC (CSE:ISOL, OTC:LAGBF, FSE:LBGA.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of wellness products, proudly announces that it has reached a partnership agreement with Cage Warriors, Europe’s leading Mixed Martial Arts (MMA) promotion through its brand ISO-Sport.

Bio-Path Announces 1-for-10 Reverse Stock Split

Bio-Path (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announces a 1-for-10 reverse stock split of its issued and outstanding common stock, which was previously approved by the Company’s Board of Directors and stockholders.

As quoted in the

Isodiol International Inc. Is Proud to Announce the Appointment of Winter Athlete Brand Ambassadors Jazmine Fenlator, Kiley McKinnon, Kimani Griffin, Faye Gulini, and Julia Marino

Isodiol International Inc. Is Proud to Announce the Appointment of Winter Athlete Brand Ambassadors Jazmine Fenlator, Kiley McKinnon, Kimani Griffin, Faye Gulini, and Julia Marino

Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announces that Jazmine Fenlator, Kiley McKinnon, Kimani Griffin, Faye Gulini, and Julia Marino have been appointed as brand ambassadors for ISO-Sport to demonstrate and discuss the

Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma

Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces that the United States Patent and Trademark Office has issued a notice of allowance for U.S. Patent Application No. 15/095,641, entitled “Alkylphosphocholine Analogs for Multiple Myeloma Imaging

Lexaria Featured on NetworkNewsWire

Lexaria Featured on NetworkNewsWire

Lexaria Bioscience (CSE:LXX,OTCQB:LXRP) was featured in a NetworkNewsWire article regarding company’s development and out-licenses of its disruptive patented technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules.

10+ Gold Stocks to Watch

Stocks.
Expert Insights.
Industry Stats.



Give me my free report!
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
What Is In-Licensing?

URL: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/what-is-in-licensing/